EGFR and breast carcinoma: Using optical imaging, pre-clinical data in breast cancer cell lines showed that gefitinib, an EGFR tyrosine kinase inhibitor, significantly reduced the uptake of choline metabolites in the sensitive cell line BT-474 but not in the resistant cell line MDA-MB-231 [36].